...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.
【24h】

High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.

机译:在瑞士,因抗促红细胞生成素抗体引起的纯红细胞发育不全在慢性透析患者中​​普遍存在:五例报告。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Pure red-cell aplasia (PRCA) after erythropoietin (Epo) administration due to the appearance of neutralizing anti-Epo antibodies has been reported in over 200 cases between 1998 and 2002. However, large intercountry disparities were observed in the occurrence of this syndrome. METHODS: On behalf of the Swiss Society of Nephrology, a survey was conducted in all the dialysis units of Switzerland in order to collect information on the occurrence, diagnostic and evolution data of the cases observed. A questionnaire was send to the nephrologists in charge of each of the 69 dialysis units in January 2003. The clinical and biological data of the suspected cases were analysed and compared with the data provided to health authorities and pharmaceutical companies. RESULTS: A total of five cases were identified as true PRCA with demonstrated positive anti-Epo antibodies. They occurred between November 1998 and February 2002, were all treated by haemodialysis and had received Epo subcutaneously. The median appearance time of refractory anaemia after Epo initiation was 10 months (range: 7-54 months). Two cases had been treated exclusively with epoietin-alpha, one solely with epoietin-beta and the two others with a combination of both. With five cases out of a total of about 2500 dialysis patients and 2300 Epo-treated dialysis patients or an exposure rate to Epo of 9900 dialysis patient-years during a 4.3 year period, this prevalence is among the highest of those reported in European countries. CONCLUSIONS: The prevalence of PRCA after Epo administration in dialysis patients appears particularly high in Switzerland. Among the potential explanations, the most plausible are the high percentage of dialysis patients treated with Epo, the almost exclusive subcutaneous administration, the larger market distribution of the epoietin-alpha brand, the eventual disruption of the cold chain and the setting-up of a systematic national survey.
机译:背景:在1998年至2002年间,已有200例病例报告了由于出现中和性抗Epo抗体而出现促红细胞生成素(Epo)后发生的纯红细胞发育不良(PRCA)。但是,在这种情况下,国家间存在巨大差异综合症。方法:代表瑞士肾脏病学会,对瑞士所有透析部门进行了一项调查,以收集有关所观察到病例的发生,诊断和演变数据的信息。在2003年1月,向负责69个透析单位的肾脏病学家发送了一份调查问卷。分析了疑似病例的临床和生物学数据,并与提供给卫生当局和制药公司的数据进行了比较。结果:共鉴定出5例真正的PRCA,并显示出抗Epo抗体阳性。它们发生在1998年11月至2002年2月之间,均接受了血液透析治疗,并接受了皮下注射Epo。 Epo启动后难治性贫血的中位出现时间为10个月(范围:7-54个月)。其中有2例仅接受了epoietin-alpha的治疗,其中1例仅接受了epoietin-beta的治疗,另2例结合了两者的治疗。在4.3年内,总共约2500名透析患者和2300名接受Epo治疗的透析患者中​​有5例,或者Epo暴露率为9900透析患者-年,这一患病率是欧洲国家中最高的。结论:在瑞士,Epo注射后透析患者中​​PRCA的患病率特别高。在可能的解释中,最可能的原因是接受Epo治疗的透析患者比例高,几乎是全皮下给药,epoietin-alpha品牌的市场分布更大,冷链的最终破裂以及建立了Epoietin。系统的全国调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号